Divi's Laboratories Ltd
NSE:DIVISLAB

Watchlist Manager
Divi's Laboratories Ltd Logo
Divi's Laboratories Ltd
NSE:DIVISLAB
Watchlist
Price: 5 998.35 INR 0.36% Market Closed
Market Cap: 1.6T INR
Have any thoughts about
Divi's Laboratories Ltd?
Write Note

Gross Margin
Divi's Laboratories Ltd

59.8%
Current
62%
Average
43.8%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
59.8%
=
Gross Profit
48.9B
/
Revenue
81.9B

Gross Margin Across Competitors

Country IN
Market Cap 1.6T INR
Gross Margin
60%
Country US
Market Cap 1.3T USD
Gross Margin
55%
Country US
Market Cap 196.3B USD
Gross Margin
41%
Country US
Market Cap 170.3B USD
Gross Margin
60%
Country KR
Market Cap 66.5T KRW
Gross Margin
50%
Country CH
Market Cap 37.6B CHF
Gross Margin
29%
Country US
Market Cap 38.5B USD
Gross Margin
55%
Country US
Market Cap 36.7B USD
Gross Margin
35%
Country US
Market Cap 26.4B USD
Gross Margin
59%
Country US
Market Cap 23B USD
Gross Margin
35%
Country US
Market Cap 22.3B USD
Gross Margin
64%
No Stocks Found

Divi's Laboratories Ltd
Glance View

Market Cap
1.6T INR
Industry
Life Sciences Tools & Services

Divi's Laboratories Ltd. is a prominent player in the pharmaceutical industry, primarily known for its role as a leading manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Founded in 1990, the company has established a robust reputation for its high-quality products and commitment to research and development. With an extensive product portfolio that serves a multitude of therapeutic areas, including pain management, oncology, and cardiovascular treatments, Divi's has positioned itself as a trusted partner to both domestic and global pharmaceutical companies. The company's state-of-the-art manufacturing facilities, compliant with international regulatory standards, ensure that it meets the growing demand for cost-effective and high-quality APIs, which is increasingly vital as the world turns to generics and specialty medicines. For investors, Divi's Laboratories presents a compelling opportunity anchored in its sustainable growth trajectory and financial resilience. Over the years, the company has demonstrated strong revenue growth and healthy profit margins, reflecting its operational efficiency and strategic focus on innovation. With a diversified customer base across more than 95 countries, the company is well-positioned to capitalize on emerging market trends and the ongoing expansion in global healthcare requirements. As healthcare systems evolve and the demand for affordable pharmaceuticals surges, Divi’s commitment to excellence and innovation keeps it at the forefront of the industry, making it an attractive investment for those looking to align with a company that not only generates value but also significantly contributes to global health outcomes.

DIVISLAB Intrinsic Value
2 897.57 INR
Overvaluation 52%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
59.8%
=
Gross Profit
48.9B
/
Revenue
81.9B
What is the Gross Margin of Divi's Laboratories Ltd?

Based on Divi's Laboratories Ltd's most recent financial statements, the company has Gross Margin of 59.8%.